The 5 Medical Import Giants in Latin America 2024 (Express Guide for Manufacturers)

If you manufacture medical devices or pharma, 2024 gives you a clear map to prioritize expansion. The rule is simple: enter where spend already flows and build local presence fast.

(Totals combine HS 90 “Optical, photo, technical, medical apparatus” + HS 30 “Pharmaceutical products.”)

Top 5 (HS 90 + HS 30) with an execution focus

1) Mexico — ~US$27.35B

Maquiladora clusters + the U.S. border = high rotation.

What a manufacturer does here: pick a distributor covering IMSS/ISSSTE + private chains, hold rotation inventory, and secure local after-sales support.

2) Brazil — ~US$21.26B

Massive volume and a public/private mix.

Key action: partner with a track record in SUS tenders and premium hospitals; plan for Anvisa timelines and a reimbursement-based pricing model.

3) Argentina — ~US$4.32B

Sustained demand despite macro volatility.

Tactical move: push diagnostics/consumables with import timing and clear replenishment agreements.

4) Chile — ~US$4.11B

Reliable payer, agile processes.

Strategy: prioritize high-value lines (monitoring/imaging) and assign a dedicated KAM for private networks.

5) Ecuador — ~US$1.78B

Compact market on the rise.

How to enter: Andean distributor with national coverage and sequential registrations by portfolio.

Note: Colombia likely lands in the Top 5 once the full public 2024 category breakdown is released; the latest visible split is 2023.

The essentials (to decide today)

• Real 80/20: Mexico + Brazil concentrate the lion’s share of spend. If your team is lean, start there and use the rest as expansion.

• Speed to entry = edge: registration, inventory, and local technical service are what set you apart in the first 12 weeks.

• The right distributor > many distributors: prioritize one with proven wins in public procurement and major private chains. Ask for 3 auditable references and set quarterly KPIs.

Country quick checklist (for manufacturers)

• Mexico: (1) Distributor with IMSS/ISSSTE cases, (2) 60–90 days minimum stock, (3) in-situ clinical training.

• Brazil: (1) Anvisa roadmap, (2) channel-based pricing (SUS vs. private), (3) documented after-sales SLAs.

• Southern Cone (ARG/CHI): (1) quarterly logistics forecasting, (2) focus on value lines, (3) contracts with installation/training targets.

• Ecuador: (1) registration sequence, (2) single national coverage, (3) consumption-based replenishment plan.

The simple message

Don’t try to be everywhere. Win first in Mexico and Brazil; consolidate in Argentina/Chile; scale into Ecuador (and add Colombia once 2024 is fully public). The manufacturer who combines registration + service + availability keeps the reorders.

Sources (verifiable)

• Mexico – HS 90 (2024) and HS 30 (2024): UN Comtrade via Trading Economics, “Mexico Imports of Optical, photo, technical, medical apparatus” and “Pharmaceutical products.”

• Brazil – HS 90 (2024) and HS 30 (2024): UN Comtrade via Trading Economics, “Brazil Imports of Optical, photo, technical, medical apparatus” and “Pharmaceutical products.”

• Argentina – HS 90 (2024) and HS 30 (2024): UN Comtrade via Trading Economics, “Argentina Imports of Optical, photo, technical, medical apparatus” and “Pharmaceutical products.”

• Chile – HS 90 (2024) and HS 30 (2024): UN Comtrade via Trading Economics, “Chile Imports of Optical, photo, technical, medical apparatus” and “Pharmaceutical products.”

• Ecuador – HS 90 (2024) and HS 30 (2024): UN Comtrade via Trading Economics, “Ecuador Imports of Optical, photo, technical, medical apparatus” and “Pharmaceutical products.”

• Brazil devices (sector 2024): ABIMO / Datamar News annual 2024 summary.

• Colombia (reference 2023): UN Comtrade via Trading Economics, “Colombia Imports of Pharmaceutical products” and “Optical, photo, technical, medical apparatus.”